Oppenheimer Weighs in on Motus GI Holdings, Inc.’s Q1 2022 Earnings (NASDAQ:MOTS)

Motus GI Holdings, Inc. (NASDAQ:MOTS – Get Rating) – Oppenheimer issued their Q1 2022 earnings per share (EPS) estimates for Motus GI in a report issued on Monday, April 25th. Oppenheimer analyst S. Lichtman expects that the company will post earnings of ($0.11) per share for the quarter. Oppenheimer also issued estimates for Motus GI’s Q2 2022 earnings at ($0.12) EPS and Q4 2022 earnings at ($0.13) EPS.

Motus GI (NASDAQ:MOTS – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. Motus GI had a negative return on equity of 83.71% and a negative net margin of 4,867.77%. During the same quarter in the prior year, the business earned ($0.12) earnings per share.

A number of other brokerages also recently commented on MOTS. Alliance Global Partners decreased their price target on Motus GI from $1.75 to $1.40 in a research report on Wednesday, January 26th. Colliers Securities reaffirmed a “buy” rating on shares of Motus GI in a research report on Tuesday, March 22nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $1.48.

Shares of MOTS opened at $0.26 on Wednesday. The company has a current ratio of 8.26, a quick ratio of 8.09 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $14.34 million, a price-to-earnings ratio of -0.48 and a beta of 2.40. The stock has a 50 day moving average of $0.34 and a 200 day moving average of $0.45. Motus GI has a 12 month low of $0.26 and a 12 month high of $1.62.

A number of large investors have recently added to or reduced their stakes in the business. Morgan Stanley increased its position in Motus GI by 41.7% in the second quarter. Morgan Stanley now owns 51,000 shares of the company’s stock worth $53,000 after buying an additional 15,000 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Motus GI by 20.4% in the third quarter. Millennium Management LLC now owns 118,652 shares of the company’s stock worth $82,000 after acquiring an additional 20,110 shares during the period. BlackRock Inc. boosted its holdings in shares of Motus GI by 13.5% in the third quarter. BlackRock Inc. now owns 202,808 shares of the company’s stock worth $139,000 after acquiring an additional 24,100 shares during the period. Citadel Advisors LLC boosted its holdings in shares of Motus GI by 276.3% in the second quarter. Citadel Advisors LLC now owns 46,447 shares of the company’s stock worth $48,000 after acquiring an additional 34,103 shares during the period. Finally, LPL Financial LLC bought a new position in shares of Motus GI in the fourth quarter worth $25,000. 13.36% of the stock is owned by institutional investors and hedge funds.

About Motus GI (Get Rating)

Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Featured Stories

Receive News & Ratings for Motus GI Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Motus GI and related companies with MarketBeat.com’s FREE daily email newsletter.